Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Vincent et al.
, Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
, Virol. J. 2:69, 2005, doi:10.1186/1743-422X-2-69 (In Vitro)
study, SARS-CoV-1, not included in the study count or percentages. CQ has strong antiviral effects on SARS CoV infection when cells treated either before or after exposure, suggesting prophylactic and treatment use. Describes three mechanisms by which the drug might work and suggests it may have both a prophylactic and therapeutic role in coronavirus infections.14 In Vitro studies
support the efficacy of HCQ [Andreani, Clementi, Dang, Delandre, Faísca, Hoffmann, Liu, Ou, Purwati, Sheaff, Wang, Wang (B), Yao, Yuan]
Vincent et al., 22 Oct 2005, peer-reviewed, 8 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
Abstract: Virology Journal
Chloroquine is a potent inhibitor of SARS coronavirus infection and
Martin J Vincent1, Eric Bergeron2, Suzanne Benjannet2, Bobbie R Erickson1,
Pierre E Rollin1, Thomas G Ksiazek1, Nabil G Seidah2 and Stuart T Nichol*1
Address: 1Special Pathogens Brach, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road,
Atlanta, Georgia, 30333, USA and 2Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, 110 Pine Ave West,
Montreal, QCH2W1R7, Canada
Email: Martin J Vincent - firstname.lastname@example.org; Eric Bergeron - email@example.com; Suzanne Benjannet - firstname.lastname@example.org;
Bobbie R Erickson - BErickson1@cdc.gov; Pierre E Rollin - PRollin@cdc.gov; Thomas G Ksiazek - TKsiazek@cdc.gov;
Nabil G Seidah - email@example.com; Stuart T Nichol* - SNichol@cdc.gov
* Corresponding author
Published: 22 August 2005
Virology Journal 2005, 2:69
Received: 12 July 2005
Accepted: 22 August 2005
This article is available from: http://www.virologyj.com/content/2/1/69
© 2005 Vincent et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
severe acute respiratory syndrome coronaviruschloroquineinhibitiontherapy
Background: Severe acute respiratory syndrome (SARS) is caused by a newly discovered
coronavirus (SARS-CoV). No effective prophylactic or post-exposure therapy is currently available.
Results: We report, however, that chloroquine has strong antiviral effects on SARS-CoV infection
of primate cells. These inhibitory effects are observed when the cells are treated with the drug
either before or after exposure to the virus, suggesting both prophylactic and therapeutic
advantage. In addition to the well-known functions of chloroquine such as elevations of endosomal
pH, the drug appears to interfere with terminal glycosylation of the cellular receptor, angiotensinconverting enzyme 2. This may negatively influence the virus-receptor binding and abrogate the
infection, with further ramifications by the elevation of vesicular pH, resulting in the inhibition of
infection and spread of SARS CoV at clinically admissible concentrations.
Conclusion: Chloroquine is effective in preventing the spread of SARS CoV in cell culture.
Favorable inhibition of virus spread was observed when the cells were either treated with
chloroquine prior to or after SARS CoV infection. In addition, the indirect immunofluorescence
assay described herein represents a simple and rapid method for screening SARS-CoV antiviral
Severe acute respiratory syndrome (SARS) is an emerging
disease that was first reported in Guangdong Province,
China, in late 2002. The disease rapidly spread to at least
30 countries within months of its first appearance, and
concerted worldwide efforts led to the identification of
the etiological agent as SARS coronavirus (SARS-CoV), a
novel member of the family Coronaviridae . Complete
genome sequencing of SARS-CoV [2,3] confirmed that
this pathogen is not closely related to any of the
Page 1 of 10
(page number not for citation purposes)
Virology Journal 2005, 2:69
previously established coronavirus groups. Budding of..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.